Tarsus Pharmaceuticals (TARS) Debt to Equity (2022 - 2025)
Tarsus Pharmaceuticals (TARS) has 4 years of Debt to Equity data on record, last reported at $0.21 in Q4 2025.
- For Q4 2025, Debt to Equity fell 34.08% year-over-year to $0.21; the TTM value through Dec 2025 reached $0.21, down 34.08%, while the annual FY2025 figure was $0.21, 34.08% down from the prior year.
- Debt to Equity reached $0.21 in Q4 2025 per TARS's latest filing, down from $0.22 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.32 in Q4 2024 and bottomed at $0.09 in Q2 2022.
- Average Debt to Equity over 4 years is $0.18, with a median of $0.16 recorded in 2023.
- Peak YoY movement for Debt to Equity: surged 117.17% in 2024, then tumbled 34.08% in 2025.
- A 4-year view of Debt to Equity shows it stood at $0.1 in 2022, then surged by 50.25% to $0.15 in 2023, then surged by 111.38% to $0.32 in 2024, then crashed by 34.08% to $0.21 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.21 in Q4 2025, $0.22 in Q3 2025, and $0.22 in Q2 2025.